The race is on to bring the predictive and diagnostic power of genome sequencing to health care. The trick is to do the sequencing and analysis quickly and inexpensively. We’ve seen several substantial venture investments in companies with different approaches this year — like Omicia and DNAnexus.
The latest is Provo, Utah-based Tute Genomics, which has just raised $2.3 million in venture funding led by U.K.-based Eurovestech. Peak Ventures and a number of angel investors also participated in the investment round. The company previously took a seed round of $1.5 million in late 2013.
Tute says it has developed a comprehensive cloud-based genome analytics platform that lets clinicians and researchers identify disease genes and biomarkers in complex genome-sequencing data. Nearly 10,000 samples have already been processed by the platform, and Tute says it has commercial agreements in place with clinical labs, molecular diagnostic companies, and research institutions.
“We are at a pivotal time in genomics as the health care community adopts next-generation sequencing and seeks new approaches for the diagnosis, treatment, and prevention of disease,” said Tute CEO Reid Robison, M.D. “One of the main barriers to making personalized, genome-guided medicine a reality is data analysis, and Tute’s platform drastically decreases the complexity and cost of analyzing genomic data sets.”
Tute lists as customers the University of Southern California and Affiliated Genetics.